Stay updated with breaking news from Vectr Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GEORGE TOWN, Cayman Islands-Aries I Acquisition Corporation announced the appointments of Mr. Aaron Ratner and Mr. Paul Wolfe to the Board of Directors. Mr. Aaron Ratner,... | October 13, 2021
Engine Biosciences, Singapore- and San Carlos, CA-based company deciphering complex biology to create medicines , raised $43m in Series A funding round. The round was led by Polaris Partners qith participation from new investors Invus and one of the world’s premier institutional investors, based in Singapore, as well as existing investors 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio. Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors. The company, which has now ...
SG-based Engine Biosciences raises $43m Series A led by Polaris Partners Jeffrey Lu, Co-Founder and CEO, Engine Biosciences. May 26, 2021 Singapore and Silicon Valley-based biotech firm Engine Biosciences on Wednesday announced it has raised $43 million (S$57 million) in a Series A round led by US-based healthcare and technology investor Polaris Partners. The round was joined by private equity firm Invus and an undisclosed institutional investor based in Singapore, the firm said in a statement. Existing investors that participated in the financing include 6 Dimensions Capital, WuXi AppTec, DH...
Engine Biosciences, a Singapore- and Silicon Valley-based company with an artificial intelligence-enabled technology platform that is designed to discover new biology targets and disease-causing links amongst known targets, has generated US$43m in a Series A funding round.
MedCity News Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, "deciphering biology" to find new cancer drugs. Shares0 Drug discovery startup Engine Biosciences has leveraged its computational technology into potential new drugs for itself and its pharmaceutical partners. Now the company has $43 million in financing to continue that work as it looks ahead to its...